



Announcement Summary

Entity name

IMPEDIMED LIMITED

Announcement Type

New announcement

Date of this announcement

6/2/2025

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	Warrants	12,491,870

Proposed +issue date

6/2/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

IMPEDIMED LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

65089705144

1.3 ASX issuer code

IPD

1.4 The announcement is

New announcement

1.5 Date of this announcement

6/2/2025

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

New class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

No

Will the entity be seeking quotation of the 'new' class of +securities on ASX?

No

ASX +security code

New class-code to be confirmed

+Security description

Warrants

+Security type

Other

Number of +securities proposed to be issued

12,491,870

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

The Warrants are being issued in accordance with the Credit Agreement between the Company's wholly owned subsidiary, ImpediMed Inc, and SWK Funding LLC, a subsidiary of SWK Holdings (SWK). If any Warrants are exercised by SWK, consideration is payable by SWK equal to the number of Warrants specified in an exercise notice multiplied by



the exercise price (being \$0.05139 per Warrant, subject to adjustment in accordance with the Warrant terms). The total amount receivable by the Company, if all 18,737,805 Warrants are exercised, is \$962,935.80 (subject to any adjustments).

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

0.051390

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Refer to the ASX announcement released on Thursday, 6 February 2025. Company announcements can be found at <https://www.impedimed.com/about/investors/>

Part 7C - Timetable

7C.1 Proposed +issue date

6/2/2025

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

18,737,805

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

No

7E.2 Is the proposed issue to be underwritten?



No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Fees and costs incurred by the Company in connection with the issue of Warrants include share registry fees, legal, and other external adviser fees.

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

The issue of the Warrants is in connection with the Credit Agreement entered into with SWK for a two-tranche financing facility of up to US\$15m.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

12,491,870 Warrants are to be issued on 6 February 2025 in connection with the Company's US\$10m drawdown of the financing facility provided by SWK and 6,245,935 Warrants are to be issued in or around July 2025 if the Company's wholly owned subsidiary, ImpediMed, Inc. receives funds in connection with a further US\$5m drawdown from such financing facility.

Each Warrant may be exercised for one fully paid ordinary share in the capital of the Company (ASX:IPD), free from encumbrances and ranking equally with existing ordinary shares.

A minimum of 1,000,000 Warrants must be exercised unless fewer are held, in which case all must be exercised.

The Warrants will expire at 5:00pm on the 7th anniversary of the date of issue.